The Diabetes Control and Complications Trial (DCCT, 1983-93) and the Epidemiology of Diabetes Interventions and Complications (EDIC, 1994-present) follow-up study have been ongoing for more than twenty years. Together, the clinical trial and subsequent follow-up have provided a plethora of information regarding the relationship among glycemia, other risk factors and long-term complications, and the effects of glycemic therapy. The DCCT was a multicenter, randomized clinical trial designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early vascular and neurologic complications of type 1 insulin-dependent diabetes mellitus (T1DM). The goal of the EDIC follow-up was to examine the longer term effects of the original DCCT interventions, especially as they apply to complications, such as cardiovascular and more advanced stages of retinal and renal disease. Clinical data collected through 2006 (EDIC Year 13) are housed at the Repository. GWAS data may be requested through dbGAP.

To examine whether intensive therapy with the goal of maintaining blood glucose concentrations close to the normal range could decrease the development and progression of diabetic complications.

HbA1c retinopathy, neuropathy, nephropathy

Type 1 diabetics less than 40 years old

The DCCT (mean follow-up of 6.5 years) demonstrated the beneficial effects of intensive therapy, aimed at achieving glycemic levels as close to the non-diabetic range as safely possible, compared with conventional therapy on retinopathy, nephropathy, and neuropathy.